EP1577816A3
(en)
*
|
1996-09-04 |
2006-08-02 |
Intertrust Technologies Corp. |
Trusted infrastructure support systems, methods and techniques for secure electronic commerce and rights management
|
US6184226B1
(en)
*
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
US6982260B1
(en)
|
1999-11-22 |
2006-01-03 |
Warner-Lambert Company |
Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
|
EP1263759B1
(en)
|
1999-12-24 |
2010-09-08 |
Aventis Pharma Limited |
Azaindoles
|
US6660731B2
(en)
*
|
2000-09-15 |
2003-12-09 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
US6638926B2
(en)
*
|
2000-09-15 |
2003-10-28 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
US7473691B2
(en)
*
|
2000-09-15 |
2009-01-06 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
JP2004518662A
(ja)
*
|
2000-12-19 |
2004-06-24 |
スミスクライン ビーチャム パブリック リミテッド カンパニー |
Gsk−3阻害剤としてのピラゾロ[3,4−c]ピリジン
|
SI1343782T1
(sl)
*
|
2000-12-21 |
2009-10-31 |
Smithkline Beecham Corp |
Pirimidinamini kot modulatorji angiogeneze
|
CA2432303C
(en)
*
|
2000-12-21 |
2010-04-13 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
US7276523B2
(en)
|
2001-03-30 |
2007-10-02 |
Smithkline Beecham Corporation |
Aminopyridine derivatives as estrogen receptor modulators
|
AU2002308748A1
(en)
|
2001-05-16 |
2002-11-25 |
Vertex Pharmaceuticals Incorporated |
Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
|
GB0115109D0
(en)
|
2001-06-21 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
US7115617B2
(en)
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
EP2264014A1
(en)
|
2001-08-31 |
2010-12-22 |
Université Louis Pasteur |
Substituted pyridazines as anti-inflammatory agents and protein kinase inhibitors
|
WO2003030909A1
(en)
*
|
2001-09-25 |
2003-04-17 |
Bayer Pharmaceuticals Corporation |
2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
|
CA2460145C
(en)
|
2001-09-26 |
2011-04-26 |
Pharmacia Italia S.P.A. |
Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
|
TWI330183B
(ja)
*
|
2001-10-22 |
2010-09-11 |
Eisai R&D Man Co Ltd |
|
SE0104140D0
(sv)
|
2001-12-07 |
2001-12-07 |
Astrazeneca Ab |
Novel Compounds
|
ATE466581T1
(de)
*
|
2001-12-07 |
2010-05-15 |
Vertex Pharma |
Verbindungen auf pyrimidin-basis als gsk-3-hemmer
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
DE60210819T2
(de)
|
2001-12-17 |
2007-04-19 |
Smithkline Beecham Corp. |
Pyrazolopyridazinderivate
|
US20030158195A1
(en)
|
2001-12-21 |
2003-08-21 |
Cywin Charles L. |
1,6 naphthyridines useful as inhibitors of SYK kinase
|
WO2003055866A1
(en)
*
|
2001-12-21 |
2003-07-10 |
Bayer Pharmaceuticals Corporation |
Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
|
CN1627944A
(zh)
|
2002-01-17 |
2005-06-15 |
神经能质公司 |
取代的喹唑啉-4-基胺类似物作为辣椒辣素调节剂
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
KR20040084896A
(ko)
*
|
2002-02-06 |
2004-10-06 |
버텍스 파마슈티칼스 인코포레이티드 |
Gsk-3의 억제제로서 유용한 헤테로아릴 화합물
|
AU2003225800A1
(en)
*
|
2002-03-15 |
2003-09-29 |
Hayley Binch |
Azolylaminoazine as inhibitors of protein kinases
|
EP1485380B1
(en)
|
2002-03-15 |
2010-05-19 |
Vertex Pharmaceuticals Incorporated |
Azolylaminoazines as inhibitors of protein kinases
|
ATE466580T1
(de)
|
2002-03-15 |
2010-05-15 |
Vertex Pharma |
Azolylaminoazine als proteinkinasehemmer
|
EP1494645A2
(en)
*
|
2002-04-05 |
2005-01-12 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Method of treating mucus hypersecretion
|
AU2003231232A1
(en)
|
2002-05-01 |
2003-11-17 |
Vertex Pharmaceuticals Incorporated |
Crystal structure of aurora-2 protein and binding pockets thereof
|
WO2003099284A1
(en)
|
2002-05-22 |
2003-12-04 |
Amgen Inc. |
Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
|
AU2003242252A1
(en)
|
2002-06-07 |
2003-12-22 |
Kyowa Hakko Kogyo Co., Ltd. |
Bicyclic pyrimidine derivatives
|
EP1527070B1
(en)
|
2002-06-14 |
2013-01-09 |
Merck Serono SA |
Azole methylidene cyanide derivatives and their use as protein kinase modulators
|
MY141867A
(en)
*
|
2002-06-20 |
2010-07-16 |
Vertex Pharma |
Substituted pyrimidines useful as protein kinase inhibitors
|
WO2004000318A2
(en)
|
2002-06-21 |
2003-12-31 |
Cellular Genomics, Inc. |
Certain amino-substituted monocycles as kinase modulators
|
CA2492673A1
(en)
*
|
2002-07-17 |
2004-01-22 |
Pharmacia Italia S.P.A. |
Heterobicyclic pyrazole derivatives as kinase inhibitors
|
WO2004010929A2
(en)
*
|
2002-07-25 |
2004-02-05 |
Scios, Inc. |
METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-β INHIBITORS
|
MXPA05001096A
(es)
|
2002-07-29 |
2005-11-23 |
Rigel Pharmaceuticals Inc |
Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
|
SI1532145T1
(sl)
*
|
2002-08-02 |
2007-02-28 |
Vertex Pharma |
Pirazolni sestavki, koristni kot inhibitorji GSK-3
|
PT1532145E
(pt)
*
|
2002-08-02 |
2007-01-31 |
Vertex Pharma |
Composiçoes de pirazole úteis como inibidores de gsk-3
|
US20060235021A1
(en)
*
|
2002-08-13 |
2006-10-19 |
Wesley Blackaby |
Phenylpyridazine derivatives as ligands for gaba receptors
|
AU2003262642B2
(en)
|
2002-08-14 |
2010-06-17 |
Vertex Pharmaceuticals Incorporated |
Protein kinase inhibitors and uses thereof
|
CA2497351C
(fr)
|
2002-09-05 |
2012-08-21 |
Aventis Pharma S.A. |
Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
|
FR2844267B1
(fr)
*
|
2002-09-05 |
2008-02-15 |
Aventis Pharma Sa |
Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
|
UA80295C2
(en)
|
2002-09-06 |
2007-09-10 |
Biogen Inc |
Pyrazolopyridines and using the same
|
US20040132730A1
(en)
*
|
2002-09-10 |
2004-07-08 |
Jonathan Axon |
Inhibitors of TGFbeta
|
JP2006512314A
(ja)
|
2002-11-01 |
2006-04-13 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Jakインヒビターおよび他のプロテインキナーゼインヒビターとしての組成物の使用
|
WO2004041810A1
(en)
|
2002-11-05 |
2004-05-21 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of jak and other protein kinases
|
ATE527250T1
(de)
|
2002-11-21 |
2011-10-15 |
Novartis Ag |
2,4,6-trisubstituierten pyrimidinen als phosphotidylinositol (pi) 3-kinase inhibitoren und deren verwendung zur behandlung von krebs
|
SI2316831T1
(sl)
*
|
2002-11-21 |
2013-07-31 |
Novartis Ag |
2-(morfolin-4-il)pirimidini kot inhibitorji fosfotidilinozitol (PI) 3-kinaze in njihova uporaba pri zdravljenju raka
|
US7759336B2
(en)
|
2002-12-10 |
2010-07-20 |
Ono Pharmaceutical Co., Ltd. |
Nitrogen-containing heterocyclic compounds and medicinal use thereof
|
FR2848554A1
(fr)
*
|
2002-12-12 |
2004-06-18 |
Aventis Pharma Sa |
Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
|
WO2004062662A1
(fr)
|
2002-12-12 |
2004-07-29 |
Aventis Pharma S.A. |
Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases
|
AU2003300898A1
(en)
|
2002-12-13 |
2004-07-09 |
Neurogen Corporation |
Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
|
US7601718B2
(en)
|
2003-02-06 |
2009-10-13 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
US7157455B2
(en)
*
|
2003-02-10 |
2007-01-02 |
Hoffmann-La Roche Inc. |
4-Aminopyrimidine-5-one derivatives
|
CA2520465A1
(en)
*
|
2003-03-28 |
2004-10-14 |
Scios Inc. |
Bi-cyclic pyrimidine inhibitors of tgf.beta.
|
AU2004230928B2
(en)
*
|
2003-04-09 |
2010-12-02 |
Exelixis, Inc. |
Tie-2 modulators and methods of use
|
CN1809351A
(zh)
*
|
2003-04-24 |
2006-07-26 |
麦克公司 |
Akt活性抑制剂
|
WO2004096808A1
(en)
*
|
2003-04-28 |
2004-11-11 |
De Novo Pharmaceuticals Limited |
Triazine compounds and their use
|
CA2528834A1
(en)
*
|
2003-06-13 |
2005-02-10 |
Arena Pharmaceuticals, Inc. |
5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases
|
AU2004257149A1
(en)
*
|
2003-06-20 |
2005-01-27 |
Coley Pharmaceutical Gmbh |
Small molecule toll-like receptor (TLR) antagonists
|
TW200510373A
(en)
|
2003-07-14 |
2005-03-16 |
Neurogen Corp |
Substituted quinolin-4-ylamine analogues
|
US7329664B2
(en)
|
2003-07-16 |
2008-02-12 |
Neurogen Corporation |
Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
|
JP4681548B2
(ja)
|
2003-07-22 |
2011-05-11 |
アステックス・セラピューティクス・リミテッド |
3,4−ジ置換1h−ピラゾール化合物および、そのサイクリン依存性キナーゼ(cdk)およびグリコーゲン・シンセターゼ・キナーゼ−3(gsk−3)調節剤としての使用
|
BRPI0413018B8
(pt)
|
2003-07-30 |
2021-05-25 |
Rigel Pharmaceuticals Inc |
composto, e, uso de um composto
|
ATE548358T1
(de)
*
|
2003-08-05 |
2012-03-15 |
Vertex Pharma |
Tetrahydrochinazolin-verbindungen als inhibitoren von spannungsabhängigen ionenkanälen
|
JP4889489B2
(ja)
*
|
2003-08-06 |
2012-03-07 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
プロテインキナーゼのインヒビターとして有用なアミノトリアゾール化合物
|
EP1668013B1
(en)
*
|
2003-09-23 |
2012-02-22 |
Vertex Pharmaceuticals Incorporated |
Pyrazolopyrrole derivatives as protein kinase inhibitors
|
GB0323137D0
(en)
|
2003-10-03 |
2003-11-05 |
Chang Lisa C W |
2,4,6- Trisubstituted pyrimidines and their different uses
|
ES2328820T3
(es)
*
|
2003-10-17 |
2009-11-18 |
Astrazeneca Ab |
Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer.
|
WO2005047268A2
(en)
*
|
2003-11-10 |
2005-05-26 |
X-Ceptor Therapeutics, Inc. |
Substituted pyrimidine compositions and methods of use
|
TW200528106A
(en)
|
2003-11-10 |
2005-09-01 |
Synta Pharmaceuticals Corp |
Pyridine compounds
|
PL1689715T3
(pl)
*
|
2003-12-03 |
2011-07-29 |
Ym Biosciences Australia Pty |
Inhibitory tubuliny
|
JP2007513184A
(ja)
*
|
2003-12-04 |
2007-05-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
プロテインキナーゼのインヒビターとして有用なキノキサリン
|
MXPA06006532A
(es)
*
|
2003-12-09 |
2006-08-23 |
Vertex Pharma |
Derivados de naftiridina y su uso como moduladores de receptores muscarinicos.
|
US7572914B2
(en)
|
2003-12-19 |
2009-08-11 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
TW200530235A
(en)
|
2003-12-24 |
2005-09-16 |
Renovis Inc |
Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
|
KR20070026390A
(ko)
|
2004-01-23 |
2007-03-08 |
암젠 인코포레이션 |
화합물 및 사용방법
|
US7626030B2
(en)
|
2004-01-23 |
2009-12-01 |
Amgen Inc. |
Compounds and methods of use
|
WO2005077938A1
(en)
*
|
2004-02-11 |
2005-08-25 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
CA2561718A1
(en)
|
2004-04-13 |
2005-10-27 |
Icagen, Inc. |
Polycyclic pyridines as potassium ion channel modulators
|
JP2007533753A
(ja)
*
|
2004-04-23 |
2007-11-22 |
タケダ サン ディエゴ インコーポレイテッド |
インドール誘導体及びキナーゼ阻害剤としてのその使用
|
US7793137B2
(en)
|
2004-10-07 |
2010-09-07 |
Cisco Technology, Inc. |
Redundant power and data in a wired data telecommunincations network
|
CA2565411C
(en)
|
2004-05-14 |
2010-04-20 |
Millennium Pharmaceuticals, Inc. |
Compounds and methods for inhibiting mitotic progression
|
EP1604988A1
(en)
*
|
2004-05-18 |
2005-12-14 |
Sanofi-Aventis Deutschland GmbH |
Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
|
EP1598348A1
(en)
*
|
2004-05-18 |
2005-11-23 |
Aventis Pharma Deutschland GmbH |
Novel pyridazinone derivatives as inhibitors of CDK2
|
DE102004028862A1
(de)
*
|
2004-06-15 |
2005-12-29 |
Merck Patent Gmbh |
3-Aminoindazole
|
GB0415364D0
(en)
*
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
WO2006012624A2
(en)
*
|
2004-07-21 |
2006-02-02 |
The Regents Of The University Of California |
Mechanism-based crosslinkers
|
WO2006023931A2
(en)
|
2004-08-18 |
2006-03-02 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
JP5006194B2
(ja)
|
2004-08-19 |
2012-08-22 |
ディーエスエム アイピー アセッツ ビー.ブイ. |
高沸点の空気および/または温度感受性有用生成物の混合物の精留方法
|
GB0419416D0
(en)
*
|
2004-09-01 |
2004-10-06 |
Inst Of Ex Botany Ascr |
4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof
|
CA2579143A1
(en)
|
2004-09-13 |
2006-03-23 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
US7622486B2
(en)
*
|
2004-09-23 |
2009-11-24 |
Reddy Us Therapeutics, Inc. |
Pyridine compounds, process for their preparation and compositions containing them
|
TW200624431A
(en)
|
2004-09-24 |
2006-07-16 |
Hoffmann La Roche |
Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
|
US7285569B2
(en)
|
2004-09-24 |
2007-10-23 |
Hoff Hoffmann-La Roche Inc. |
Tricycles, their manufacture and use as pharmaceutical agents
|
RU2380101C2
(ru)
|
2004-09-30 |
2010-01-27 |
Тиботек Фармасьютикалз Лтд. |
Бициклические пиримидины, ингибирующие hcv
|
TW200621251A
(en)
|
2004-10-12 |
2006-07-01 |
Neurogen Corp |
Substituted biaryl quinolin-4-ylamine analogues
|
JP2008516973A
(ja)
*
|
2004-10-15 |
2008-05-22 |
タケダ サン ディエゴ インコーポレイテッド |
キナーゼ阻害剤
|
TW200621257A
(en)
|
2004-10-20 |
2006-07-01 |
Astellas Pharma Inc |
Pyrimidine derivative fused with nonaromatic ring
|
WO2006050359A2
(en)
|
2004-11-02 |
2006-05-11 |
Northwestern University |
Pyridazine compounds and methods
|
AU2005302225B2
(en)
|
2004-11-02 |
2012-05-24 |
Centre National De La Recherche Scientifique |
Pyridazine compounds, compositions and methods
|
BRPI0517737A
(pt)
|
2004-11-17 |
2008-10-21 |
Miikana Therapeutics Inc |
inibidores de quinase
|
CA2584295C
(en)
|
2004-11-24 |
2014-08-26 |
Rigel Pharmaceuticals, Inc. |
Spiro-2, 4-pyrimidinediamine compounds and their uses
|
EP1827434B1
(en)
|
2004-11-30 |
2014-01-15 |
Amgen Inc. |
Quinolines and quinazoline analogs and their use as medicaments for treating cancer
|
US20060128710A1
(en)
*
|
2004-12-09 |
2006-06-15 |
Chih-Hung Lee |
Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
|
EP1831216A2
(en)
*
|
2004-12-23 |
2007-09-12 |
Pfizer Products Inc. |
Heteroaromatic derivatives useful as anticancer agents
|
EP1841760B1
(en)
*
|
2004-12-30 |
2011-08-10 |
Exelixis, Inc. |
Pyrimidine derivatives as kinase modulators and method of use
|
DK1856135T3
(da)
|
2005-01-19 |
2010-04-12 |
Rigel Pharmaceuticals Inc |
Prodrugs af 2,4-pyrimidindiamin-forbindelser og deres anvendelser
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
AR054425A1
(es)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
ES2336243T3
(es)
*
|
2005-01-26 |
2010-04-09 |
Schering Corporation |
Derivados de 3-(indazol-5-il)-(1,2,4)triazina y composiciones similares como inhibidores de proteina quinasa para el tratamiento del cancer.
|
US20060178388A1
(en)
|
2005-02-04 |
2006-08-10 |
Wrobleski Stephen T |
Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
|
NZ561145A
(en)
|
2005-02-04 |
2011-02-25 |
Astrazeneca Ab |
Pyrazolylaminopyridine derivatives useful as kinase inhibitors
|
KR101362621B1
(ko)
*
|
2005-02-16 |
2014-02-13 |
아스트라제네카 아베 |
화합물
|
US20080161278A1
(en)
*
|
2005-03-23 |
2008-07-03 |
Astrazeneca Ab |
2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity
|
US7297700B2
(en)
|
2005-03-24 |
2007-11-20 |
Renovis, Inc. |
Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
|
JP2008534479A
(ja)
|
2005-03-25 |
2008-08-28 |
テイボテク・フアーマシユーチカルズ・リミテツド |
Hcvの複素二環式阻害剤
|
BRPI0609965A2
(pt)
*
|
2005-04-05 |
2011-10-11 |
Astrazeneca Ab |
composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, métodos para produzir um efeito ant-proliferativo em um animal de sangue quente, para tratar uma doença ou condição médica, para a prevenção ou tratamento de tumores, e para o tratamento de cáncer, e, processo para a preparação de um composto ou de um sal farmaceuticamente aceitável do mesmo
|
GB0507347D0
(en)
*
|
2005-04-12 |
2005-05-18 |
Astrazeneca Ab |
Chemical compounds
|
JP2008535876A
(ja)
|
2005-04-14 |
2008-09-04 |
エフ.ホフマン−ラ ロシュ アーゲー |
アミノピラゾール誘導体、これらの製造、及び医薬製剤としての使用。
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Alternative amide derivatives and methods of use
|
ES2545382T3
(es)
|
2005-04-28 |
2015-09-10 |
Mitsubishi Tanabe Pharma Corporation |
Derivado de cianopiridina y su uso como medicamento
|
MX2007013595A
(es)
*
|
2005-05-04 |
2008-01-24 |
Renovis Inc |
Compuestos heterociclicos fusionados y composiciones y usos de estos.
|
US20080207594A1
(en)
|
2005-05-04 |
2008-08-28 |
Davelogen Aktiengesellschaft |
Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
|
JP2008540391A
(ja)
*
|
2005-05-05 |
2008-11-20 |
アストラゼネカ アクチボラグ |
ピラゾリルアミノ置換ピリミジン、および癌の処置におけるそれらの使用
|
AR056347A1
(es)
|
2005-05-12 |
2007-10-03 |
Tibotec Pharm Ltd |
Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
|
WO2006123113A2
(en)
|
2005-05-16 |
2006-11-23 |
Astrazeneca Ab |
Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
|
EP1899332A1
(en)
|
2005-06-24 |
2008-03-19 |
Gilead Sciences, Inc. |
Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c.
|
ES2270715B1
(es)
|
2005-07-29 |
2008-04-01 |
Laboratorios Almirall S.A. |
Nuevos derivados de pirazina.
|
EP1917259B1
(en)
*
|
2005-08-18 |
2012-01-25 |
Vertex Pharmaceuticals Incorporated |
Pyrazine kinase inhibitors
|
WO2007023382A2
(en)
*
|
2005-08-25 |
2007-03-01 |
Pfizer Inc. |
Pyrimidine amino pyrazole compounds, potent kinase inhibitors
|
EP2258358A3
(en)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
EP2275095A3
(en)
|
2005-08-26 |
2011-08-17 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
WO2007031838A1
(en)
|
2005-09-16 |
2007-03-22 |
Ranbaxy Laboratories Limited |
Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
|
EP1928456B1
(en)
*
|
2005-09-30 |
2015-04-22 |
Miikana Therapeutics, Inc. |
Substituted pyrazole compounds
|
UA96427C2
(en)
*
|
2005-09-30 |
2011-11-10 |
Мийкана Терапьютикс, Инк. |
Substituted pyrazole compounds
|
ES2274712B1
(es)
|
2005-10-06 |
2008-03-01 |
Laboratorios Almirall S.A. |
Nuevos derivados imidazopiridina.
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
GB0520657D0
(en)
*
|
2005-10-11 |
2005-11-16 |
Ludwig Inst Cancer Res |
Pharmaceutical compounds
|
CA2625153A1
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
AU2006307657B2
(en)
*
|
2005-10-28 |
2010-10-28 |
Astrazeneca Ab |
4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
|
JP2009513672A
(ja)
|
2005-10-31 |
2009-04-02 |
ブレインセルス,インコーポレイティド |
神経発生のgaba受容体媒介調節
|
US7820685B2
(en)
*
|
2005-11-03 |
2010-10-26 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
ZA200803887B
(en)
|
2005-11-08 |
2009-12-30 |
Vertex Pharma |
Heterocyclic modulators of ATP-Binding Cassette transporters
|
US7713987B2
(en)
|
2005-12-06 |
2010-05-11 |
Rigel Pharmaceuticals, Inc. |
Pyrimidine-2,4-diamines and their uses
|
US8546404B2
(en)
|
2005-12-13 |
2013-10-01 |
Merck Sharp & Dohme |
Compounds that are ERK inhibitors
|
US7572809B2
(en)
|
2005-12-19 |
2009-08-11 |
Hoffmann-La Roche Inc. |
Isoquinoline aminopyrazole derivatives
|
WO2007075847A2
(en)
*
|
2005-12-20 |
2007-07-05 |
Takeda Pharmaceutical Company Limited |
Glucokinase activators
|
AU2007207533B8
(en)
|
2006-01-17 |
2012-06-28 |
Vertex Pharmaceuticals Incorporated |
Azaindoles useful as inhibitors of Janus kinases
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
WO2007097937A1
(en)
|
2006-02-16 |
2007-08-30 |
Schering Corporation |
Pyrrolidine derivatives as erk inhibitors
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
WO2007104035A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
PE20080145A1
(es)
|
2006-03-21 |
2008-02-11 |
Janssen Pharmaceutica Nv |
Tetrahidro-pirimidoazepinas como moduladores de trpv1
|
WO2007117692A2
(en)
*
|
2006-04-11 |
2007-10-18 |
Vertex Pharmaceuticals Incorporated |
Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
|
CA2650711A1
(en)
|
2006-04-28 |
2007-11-08 |
Northwestern University |
Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
|
CA2651862A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
US20100009983A1
(en)
*
|
2006-05-09 |
2010-01-14 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
EP2021000A2
(en)
|
2006-05-09 |
2009-02-11 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
RU2444521C2
(ru)
|
2006-06-27 |
2012-03-10 |
Такеда Фармасьютикал Компани Лимитед |
Конденсированные циклические соединения
|
JP2009541480A
(ja)
*
|
2006-06-30 |
2009-11-26 |
アストラゼネカ アクチボラグ |
癌の治療において有用なピリミジン誘導体
|
AU2007269540B2
(en)
*
|
2006-07-05 |
2013-06-27 |
Exelixis, Inc. |
Methods of using IGF1R and Abl kinase modulators
|
US8063050B2
(en)
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
UA95641C2
(en)
*
|
2006-07-06 |
2011-08-25 |
Эррей Биофарма Инк. |
Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
|
RU2481336C2
(ru)
*
|
2006-07-06 |
2013-05-10 |
Эррэй Биофарма Инк. |
Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт
|
US8338435B2
(en)
|
2006-07-20 |
2012-12-25 |
Gilead Sciences, Inc. |
Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
|
AU2007292848A1
(en)
*
|
2006-09-08 |
2008-03-13 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
US20080103165A1
(en)
*
|
2006-09-19 |
2008-05-01 |
Braincells, Inc. |
Ppar mediated modulation of neurogenesis
|
US20100120717A1
(en)
|
2006-10-09 |
2010-05-13 |
Brown Jason W |
Kinase inhibitors
|
EP2223925A1
(en)
*
|
2006-10-09 |
2010-09-01 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
MX2009004140A
(es)
|
2006-10-21 |
2009-07-10 |
Abbott Gmbh & Co Kg |
Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3.
|
MX2009004807A
(es)
*
|
2006-11-02 |
2009-06-15 |
Vertex Pharma |
Aminopiridinas y aminopirimidinas utiles como inhibidores de proteina cinasa.
|
DE602007007985D1
(de)
*
|
2006-12-19 |
2010-09-02 |
Vertex Pharma |
Als inhibitoren von proteinkinasen geeignete aminopyrimidine
|
US8637531B2
(en)
|
2006-12-26 |
2014-01-28 |
Gilead Sciences, Inc. |
Pyrido(3,2-d)pyridmidines useful for treating viral infections
|
WO2008077649A1
(en)
|
2006-12-26 |
2008-07-03 |
Gilead Sciences, Inc. |
Pyrido(3,2-d)pyrimidines useful for treating viral infectons
|
TW200840584A
(en)
|
2006-12-26 |
2008-10-16 |
Gilead Sciences Inc |
Pyrido(3,2-d)pyrimidines useful for treating viral infections
|
CA2675558A1
(en)
|
2007-02-06 |
2008-08-14 |
Novartis Ag |
Pi 3-kinase inhibitors and methods of their use
|
JP2010518064A
(ja)
*
|
2007-02-12 |
2010-05-27 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Adおよび関連状態の治療のためのピペラジン誘導体
|
AU2008216842A1
(en)
*
|
2007-02-12 |
2008-08-21 |
Merck Sharp & Dohme Corp. |
Piperidine derivatives
|
CN101622015A
(zh)
|
2007-03-05 |
2010-01-06 |
协和发酵麒麟株式会社 |
药物组合物
|
RU2009137390A
(ru)
*
|
2007-03-09 |
2011-04-20 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Аминопиримидины, пригодные в качестве ингибиторов протеинкиназ
|
AU2008226461A1
(en)
|
2007-03-09 |
2008-09-18 |
Vertex Pharmaceuticals Incorporated |
Aminopyridines useful as inhibitors of protein kinases
|
CN101663295B
(zh)
*
|
2007-03-09 |
2014-11-05 |
沃泰克斯药物股份有限公司 |
可用作蛋白激酶抑制剂的氨基嘧啶类化合物
|
CA2683785A1
(en)
|
2007-04-13 |
2008-10-23 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
EP2155742A1
(en)
*
|
2007-04-18 |
2010-02-24 |
AstraZeneca AB |
5-aminopyrazol-3-yl-3h-imidazo [4,5-b]pyridine derivatives and their use for the treatment of cancer
|
JP5389785B2
(ja)
*
|
2007-05-02 |
2014-01-15 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
キナーゼ阻害剤として有用なチアゾールおよびピラゾール
|
EP2152696B1
(en)
|
2007-05-02 |
2014-09-24 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
WO2008137622A2
(en)
*
|
2007-05-02 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
JP2010526048A
(ja)
*
|
2007-05-04 |
2010-07-29 |
アストラゼネカ アクチボラグ |
アミノ−チアゾリル−ピリミジン誘導体、および癌の治療のための該誘導体の使用
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
NZ581259A
(en)
|
2007-05-09 |
2012-07-27 |
Vertex Pharma |
Modulators of cystic fibrosis transmembrane conductance regulator
|
AU2008257044A1
(en)
*
|
2007-05-24 |
2008-12-04 |
Vertex Pharmaceuticals Incorporated |
Thiazoles and pyrazoles useful as kinase inhibitors
|
WO2008154026A1
(en)
*
|
2007-06-11 |
2008-12-18 |
Miikana Therapeutics, Inc. |
Substituted pyrazole compounds
|
EP2166854A4
(en)
*
|
2007-06-13 |
2012-05-16 |
Merck Sharp & Dohme |
TRIAZOLE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND ASSOCIATED STATES
|
EP2170859A1
(en)
|
2007-06-25 |
2010-04-07 |
F. Hoffmann-Roche AG |
Benzimidazole amido derivatives as kinase inhibitors
|
US8846683B2
(en)
|
2007-07-05 |
2014-09-30 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
AR067413A1
(es)
|
2007-07-05 |
2009-10-07 |
Genentech Inc |
Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer
|
US9409886B2
(en)
|
2007-07-05 |
2016-08-09 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
US8377937B2
(en)
*
|
2007-07-05 |
2013-02-19 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
ES2392003T3
(es)
|
2007-07-25 |
2012-12-03 |
Bristol-Myers Squibb Company |
Inhibidores de la triazina quinasa
|
TW200906818A
(en)
*
|
2007-07-31 |
2009-02-16 |
Astrazeneca Ab |
Chemical compounds
|
AU2008282156B2
(en)
|
2007-07-31 |
2014-07-17 |
Vertex Pharmaceuticals Incorporated |
Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
|
AU2008326784B2
(en)
|
2007-11-20 |
2014-04-24 |
Merck Sharp & Dohme Corp. |
Non-nucleoside reverse transcriptase inhibitors
|
EP2639223B1
(en)
|
2007-12-07 |
2017-03-29 |
Vertex Pharmaceuticals Incorporated |
Process for producing cycloalkylcarboxiamido-pyridine benzoic acids
|
CA2986286C
(en)
|
2007-12-07 |
2019-04-23 |
Vertex Pharmaceuticals Incorporated |
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
JP2011032169A
(ja)
*
|
2007-12-11 |
2011-02-17 |
Genecare Research Institute Co Ltd |
4−アミノピリミジン誘導体および該化合物を含有する医薬組成物
|
EP2224929B1
(en)
|
2007-12-17 |
2016-05-04 |
Janssen Pharmaceutica, N.V. |
Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
|
US8329709B2
(en)
*
|
2008-01-09 |
2012-12-11 |
Genentech, Inc. |
5H-cyclopenta[D]pyrimidines as AKT protein kinase inhibitors
|
JP5512545B2
(ja)
|
2008-01-09 |
2014-06-04 |
アレイ バイオファーマ、インコーポレイテッド |
Aktタンパク質キナーゼ阻害剤としてのピリミジルシクロペンタン類
|
MY152271A
(en)
|
2008-02-21 |
2014-09-15 |
Merck Sharp & Dohme |
Novel compounds that are erk inhibitors
|
JP5523352B2
(ja)
|
2008-02-28 |
2014-06-18 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Cftr修飾因子としてのへテロアリール誘導体
|
EP2262498A2
(en)
*
|
2008-03-10 |
2010-12-22 |
Vertex Pharmceuticals Incorporated |
Pyrimidines and pyridines useful as inhibitors of protein kinases
|
CL2009000904A1
(es)
*
|
2008-04-21 |
2010-04-30 |
Shionogi & Co |
Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
|
US8158656B2
(en)
*
|
2008-05-16 |
2012-04-17 |
Shenzhen Chipscreen Biosciences Ltd. |
2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
|
DK2300013T3
(en)
|
2008-05-21 |
2017-12-04 |
Ariad Pharma Inc |
PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS
|
JP2011522870A
(ja)
*
|
2008-06-11 |
2011-08-04 |
アストラゼネカ アクチボラグ |
癌および骨髄増殖性障害の処置に有用な三環式2,4−ジアミノ−l,3,5−トリアジン誘導体
|
CA2727684C
(en)
|
2008-06-12 |
2017-01-31 |
Janssen Pharmaceutica Nv |
Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor
|
WO2010002998A1
(en)
|
2008-07-03 |
2010-01-07 |
Gilead Sciences, Inc. |
2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS
|
EA201100126A1
(ru)
*
|
2008-07-03 |
2011-08-30 |
Мерк Патент Гмбх |
Нафтиридиноны в качестве ингибиторов протеинкиназ
|
WO2010014939A1
(en)
|
2008-07-31 |
2010-02-04 |
Genentech, Inc. |
Pyrimidine compounds, compositions and methods of use
|
WO2010019392A1
(en)
*
|
2008-08-13 |
2010-02-18 |
Merck Sharp & Dohme Corp. |
Purine derivatives for treatment of alzheimer's disease
|
RU2011112802A
(ru)
*
|
2008-09-03 |
2012-10-10 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Сокристаллы и содержащие их фармацевтические композиции
|
JP6144873B2
(ja)
*
|
2008-09-15 |
2017-06-07 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Ire1、src、及びabl活性を調節するための方法及び組成物
|
BRPI0919488A2
(pt)
*
|
2008-09-30 |
2015-12-01 |
Astrazeneca Ab |
composto, uso de um composto, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto
|
JP5539376B2
(ja)
*
|
2008-11-19 |
2014-07-02 |
エボテック (ユーエス) インコーポレイテッド |
Faah調整因子として有用な6,7−ジヒドロ−5h−ピロロ[3,4−d]ピリミジン−4−イル]キノリン−3−イルアミン化合物およびその使用
|
KR101048448B1
(ko)
|
2008-11-21 |
2011-07-11 |
한국화학연구원 |
신규 피라졸로[4,3-b]피리딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
|
CA2751565C
(en)
|
2009-02-05 |
2017-05-16 |
Takeda Pharmaceutical Company Limited |
Pyridazinone compounds
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
RU2529019C2
(ru)
*
|
2009-02-27 |
2014-09-27 |
Эмбит Байосайенсиз Корпорейшн |
Модулирующие jak киназу хиназолиновые производные и способы их применения
|
WO2010104851A1
(en)
*
|
2009-03-09 |
2010-09-16 |
Surface Logix, Inc. |
Rho kinase inhibitors
|
EP2411010B1
(en)
*
|
2009-03-23 |
2013-11-06 |
Msd K.K. |
Novel aminopyridine derivatives having aurora a selective inhibitory action
|
EP2411012A4
(en)
*
|
2009-03-24 |
2012-08-22 |
Msd Kk |
NOVEL AMINOPYRIDINE DERIVATIVES HAVING SELECTIVE INHIBITORY ACTION OF AURORA A
|
CN102497863A
(zh)
*
|
2009-03-24 |
2012-06-13 |
Msdk.K.公司 |
具有Aurora A选择性抑制作用的新型氨基吡啶衍生物
|
US8211901B2
(en)
|
2009-05-22 |
2012-07-03 |
Shenzhen Chipscreen Biosciences Ltd. |
Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
|
CN101906076B
(zh)
|
2009-06-04 |
2013-03-13 |
深圳微芯生物科技有限责任公司 |
作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
|
US20120238576A1
(en)
*
|
2009-06-08 |
2012-09-20 |
California Capital Equity, Llc |
Triazine Derivatives and their Therapeutical Applications
|
KR101457027B1
(ko)
*
|
2009-06-09 |
2014-10-31 |
캘리포니아 캐피탈 에쿼티, 엘엘씨 |
트리아진 유도체와 이들의 치료적 용도
|
US20120202818A1
(en)
*
|
2009-06-09 |
2012-08-09 |
California Capital Equity, Llc |
Ureidophenyl substituted triazine derivatives and their therapeutical applications
|
US20100331305A1
(en)
*
|
2009-06-24 |
2010-12-30 |
Genentech, Inc. |
Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
|
TWI468402B
(zh)
*
|
2009-07-31 |
2015-01-11 |
必治妥美雅史谷比公司 |
降低β-類澱粉生成之化合物
|
US8637525B2
(en)
|
2009-07-31 |
2014-01-28 |
Bristol-Myers Squibb Company |
Compounds for the reduction of beta-amyloid production
|
US20110053916A1
(en)
|
2009-08-14 |
2011-03-03 |
Vertex Pharmaceuticals Incorporated |
Pyrimidine compounds as tuberculosis inhibitors
|
CN102020657A
(zh)
*
|
2009-09-11 |
2011-04-20 |
上海艾力斯医药科技有限公司 |
稠合杂芳基衍生物、制备方法及其应用
|
KR101469334B1
(ko)
*
|
2009-11-12 |
2014-12-04 |
에프. 호프만-라 로슈 아게 |
N-9-치환된 퓨린 화합물, 조성물 및 사용 방법
|
CA2780018C
(en)
|
2009-11-12 |
2015-10-20 |
F. Hoffmann-La Roche Ag |
N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use
|
SG183263A1
(en)
*
|
2010-02-11 |
2012-09-27 |
Univ Vanderbilt |
Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction
|
CA2795804C
(en)
|
2010-04-07 |
2021-10-26 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
|
JP5607241B2
(ja)
|
2010-05-21 |
2014-10-15 |
ケミリア・エービー |
新規ピリミジン誘導体
|
PL2576541T3
(pl)
|
2010-06-04 |
2016-10-31 |
|
Pochodne aminopirymidyny jako modulatory lrrk2
|
US20110319409A1
(en)
*
|
2010-06-23 |
2011-12-29 |
Cox Christopher D |
7-aza-quinazoline pde10 inhibitors
|
JP5901634B2
(ja)
|
2010-09-01 |
2016-04-13 |
アムビト ビオスシエンセス コルポラチオン |
キナゾリン化合物及びその使用方法
|
MX336726B
(es)
|
2010-09-27 |
2016-01-27 |
Abbott Gmbh & Co Kg |
Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
|
WO2012059932A1
(en)
|
2010-11-01 |
2012-05-10 |
Aurigene Discovery Technologies Limited |
2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
|
CA2816957A1
(en)
|
2010-11-07 |
2012-05-10 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
PL2638031T3
(pl)
|
2010-11-10 |
2018-03-30 |
Genentech, Inc. |
Pirazolowo-aminopirymidynowe pochodne jako modulatory LRRK2
|
CN105920010A
(zh)
|
2010-12-14 |
2016-09-07 |
电泳有限公司 |
酪蛋白激酶1δ(CK1δ)抑制剂
|
BR112013015449A2
(pt)
|
2010-12-21 |
2016-09-20 |
Novartis Ag |
compostos de bi-heteroarila como inibidores de vps23
|
US9090592B2
(en)
|
2010-12-30 |
2015-07-28 |
AbbVie Deutschland GmbH & Co. KG |
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
|
WO2012101654A2
(en)
*
|
2011-01-25 |
2012-08-02 |
Sphaera Pharma Pvt. Ltd |
Novel triazine compounds
|
WO2012127032A1
(en)
|
2011-03-24 |
2012-09-27 |
Chemilia Ab |
Novel pyrimidine derivatives
|
CN111643504A
(zh)
|
2011-04-01 |
2020-09-11 |
基因泰克公司 |
Akt抑制剂化合物和化疗剂的组合以及使用方法
|
US9682082B2
(en)
|
2011-04-01 |
2017-06-20 |
Genentech, Inc. |
Combinations of AKT and MEK inhibitor compounds, and methods of use
|
RU2477723C2
(ru)
|
2011-06-16 |
2013-03-20 |
Общество С Ограниченной Ответственностью "Фьюжн Фарма" |
Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
|
EP2734520B1
(en)
|
2011-07-19 |
2016-09-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US8846656B2
(en)
|
2011-07-22 |
2014-09-30 |
Novartis Ag |
Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
|
KR20140062079A
(ko)
|
2011-08-25 |
2014-05-22 |
에프. 호프만-라 로슈 아게 |
세린/트레오닌 pak1 억제제
|
ME03332B
(me)
|
2011-09-14 |
2019-10-20 |
Samumed Llc |
Indazol-3-karboksamidi i njihova upotreba kao inhibitora signalnog puta wnt/b-katenina
|
CN103814030A
(zh)
|
2011-09-22 |
2014-05-21 |
辉瑞大药厂 |
吡咯并嘧啶及嘌呤衍生物
|
KR20140069235A
(ko)
|
2011-09-27 |
2014-06-09 |
노파르티스 아게 |
돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
|
EP2794605A1
(en)
|
2011-12-22 |
2014-10-29 |
F.Hoffmann-La Roche Ag |
2, 4-diamine-pyrimidine derivative as serine/threonine kinase inhibitors
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
AU2013205240B2
(en)
*
|
2012-03-16 |
2016-02-11 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
ES2872348T3
(es)
*
|
2012-03-19 |
2021-11-02 |
Imperial College Innovations Ltd |
Compuestos de quinazolina y su uso en terapia
|
US20130303519A1
(en)
|
2012-03-20 |
2013-11-14 |
Millennium Pharmaceuticals, Inc. |
Methods of treating cancer using aurora kinase inhibitors
|
PH12017500997A1
(en)
|
2012-04-04 |
2018-02-19 |
Samumed Llc |
Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
|
IN2014KN02601A
(ja)
|
2012-04-24 |
2015-05-08 |
Vertex Pharma |
|
EP2844658B1
(en)
*
|
2012-05-03 |
2019-03-20 |
Genentech, Inc. |
Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease
|
RU2637947C2
(ru)
*
|
2012-05-03 |
2017-12-08 |
Дженентек, Инк. |
Производные пиразоламинопиримидина в качестве модуляторов обогащенной лейциновыми повторами киназы 2
|
SG10201610869TA
(en)
|
2012-06-26 |
2017-02-27 |
Del Mar Pharmaceuticals |
Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti
|
BR112015007061B1
(pt)
*
|
2012-09-28 |
2022-10-04 |
Cancer Research Technology Limited |
Composto, composição farmacêutica e uso do composto
|
JO3470B1
(ar)
|
2012-10-08 |
2020-07-05 |
Merck Sharp & Dohme |
مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
|
EP2909181B1
(en)
*
|
2012-10-16 |
2017-08-09 |
Tolero Pharmaceuticals, Inc. |
Pkm2 modulators and methods for their use
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
BR112015011456A2
(pt)
*
|
2012-11-20 |
2017-07-11 |
Genentech Inc |
compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
|
KR102455889B1
(ko)
|
2012-11-21 |
2022-10-17 |
피티씨 테라퓨틱스, 인크. |
치환된 리버스 피리미딘 bmi-1 저해제
|
EP2943198B1
(en)
|
2013-01-08 |
2019-07-17 |
Samumed, LLC |
3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
|
CN103012428A
(zh)
|
2013-01-08 |
2013-04-03 |
中国药科大学 |
4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
|
ES2716762T3
(es)
*
|
2013-02-04 |
2019-06-14 |
Janssen Pharmaceutica Nv |
Moduladores de FLAP
|
TWI644899B
(zh)
|
2013-02-04 |
2018-12-21 |
健生藥品公司 |
Flap調節劑
|
EP2769722A1
(en)
*
|
2013-02-22 |
2014-08-27 |
Ruprecht-Karls-Universität Heidelberg |
Compounds for use in inhibiting HIV capsid assembly
|
JO3377B1
(ar)
*
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
مشتقات بيريدينيل وبيريدينيل مندمج
|
PT3527563T
(pt)
|
2013-03-12 |
2021-12-09 |
Vertex Pharma |
Inibidores de adn-pk
|
CN105263929B
(zh)
|
2013-03-14 |
2018-08-28 |
诺华股份有限公司 |
作为突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物
|
CN105209042B
(zh)
|
2013-03-22 |
2019-03-08 |
米伦纽姆医药公司 |
催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合
|
CA2928568A1
(en)
|
2013-07-26 |
2015-01-29 |
Update Pharma Inc. |
Combinatorial methods to improve the therapeutic benefit of bisantrene
|
CN105683166B
(zh)
|
2013-08-30 |
2020-06-16 |
Ptc医疗公司 |
取代的嘧啶Bmi-1抑制剂
|
WO2015028848A1
(en)
*
|
2013-09-02 |
2015-03-05 |
Piramal Enterprises Limited |
Bicyclic heterocyclic compounds as multi-kinase inhibitors
|
DK3052096T3
(en)
|
2013-10-03 |
2018-03-12 |
Kura Oncology Inc |
INHIBITORS OF ERK AND METHODS OF USE
|
CN104903312B
(zh)
*
|
2013-10-07 |
2019-01-29 |
卡德门企业有限公司 |
Rho激酶抑制剂
|
DK3057953T3
(en)
|
2013-10-17 |
2018-11-19 |
Vertex Pharma |
CO CRYSTALS OF (S) -N-METHYL-8- (1 - ((2'-METHYL- [4,5'-BIPYRIMIDIN] -6-YL) AMINO) PROPAN-2-YL) QUINOLIN-4-CARBOXAMIDE AND DEUTERATED DERIVATIVES THEREOF AS DNA-PK INHIBITORS
|
CN105848657B
(zh)
|
2013-11-12 |
2020-05-22 |
沃泰克斯药物股份有限公司 |
制备用于治疗cftr介导的疾病的药物组合物的方法
|
WO2015076801A1
(en)
*
|
2013-11-21 |
2015-05-28 |
Ptc Therapeutics, Inc. |
Substituted triazine bmi-1 inhibitors
|
EP3071553A4
(en)
|
2013-11-21 |
2017-08-02 |
PTC Therapeutics, Inc. |
Substituted pyridine and pyrazine bmi-1 inhibitors
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
CN104672250B
(zh)
*
|
2013-11-29 |
2017-11-07 |
广东东阳光药业有限公司 |
取代的杂芳基化合物及其组合物和用途
|
US10030004B2
(en)
*
|
2014-01-01 |
2018-07-24 |
Medivation Technologies Llc |
Compounds and methods of use
|
WO2015112739A1
(en)
*
|
2014-01-22 |
2015-07-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compounds and method for treating parp1-deficient cancers
|
CN104926794B
(zh)
*
|
2014-03-17 |
2017-12-05 |
广东东阳光药业有限公司 |
取代的杂芳基化合物及其组合物和用途
|
TWI675836B
(zh)
*
|
2014-03-25 |
2019-11-01 |
美商伊格尼塔公司 |
非典型蛋白質激酶c之氮雜喹唑啉抑制劑
|
US20170165230A1
(en)
|
2014-04-09 |
2017-06-15 |
Christopher Rudd |
Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
|
CN105367555B
(zh)
*
|
2014-08-07 |
2019-06-25 |
广东东阳光药业有限公司 |
取代的杂芳基化合物及其组合物和用途
|
WO2016040181A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040185A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
|
WO2016040190A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
WO2016040184A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040180A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040193A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
DK3221692T3
(da)
|
2014-11-18 |
2021-08-23 |
Vertex Pharma |
Fremgangsmåde til udførsel af tests med høj kapacitet ved hjælp af højtryksvæskekromatografi
|
TWI704151B
(zh)
*
|
2014-12-22 |
2020-09-11 |
美商美國禮來大藥廠 |
Erk抑制劑
|
ES2700200T3
(es)
*
|
2014-12-22 |
2019-02-14 |
Lilly Co Eli |
Inhibidores de ERK
|
US10227343B2
(en)
|
2015-01-30 |
2019-03-12 |
Vanderbilt University |
Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
|
EP3070084A1
(en)
*
|
2015-03-18 |
2016-09-21 |
Rottapharm Biotech S.r.l. |
New fyn kinase inhibitors
|
US10752612B2
(en)
|
2015-04-17 |
2020-08-25 |
Ludwig Institute For Cancer Research Ltd |
PLK4 inhibitors
|
EP3302465A1
(en)
|
2015-06-05 |
2018-04-11 |
Vertex Pharmaceuticals Incorporated |
Triazoles for the treatment of demyelinating diseases
|
US10285983B2
(en)
|
2015-08-03 |
2019-05-14 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
|
WO2017023987A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
US10166218B2
(en)
|
2015-08-03 |
2019-01-01 |
Samumed, Llc |
3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
WO2017024003A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10226453B2
(en)
|
2015-08-03 |
2019-03-12 |
Samumed, Llc |
3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017023986A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
|
WO2017023980A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
US10350199B2
(en)
|
2015-08-03 |
2019-07-16 |
Samumed, Llc |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
US10519169B2
(en)
|
2015-08-03 |
2019-12-31 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
US10188634B2
(en)
|
2015-08-03 |
2019-01-29 |
Samumed, Llc |
3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017023972A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10206908B2
(en)
|
2015-08-03 |
2019-02-19 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
WO2017023975A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
US10206909B2
(en)
|
2015-08-03 |
2019-02-19 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017023989A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
WO2017024010A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
US10329309B2
(en)
|
2015-08-03 |
2019-06-25 |
Samumed, Llc |
3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
US10544139B2
(en)
|
2015-11-06 |
2020-01-28 |
Samumed, Llc |
Treatment of osteoarthritis
|
GB201604647D0
(en)
*
|
2016-03-18 |
2016-05-04 |
Mission Therapeutics Ltd |
Novel compounds
|
CA3026076A1
(en)
|
2016-06-01 |
2017-12-07 |
Samumed, Llc |
Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
|
CA3038657A1
(en)
|
2016-09-27 |
2018-04-05 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors
|
MX2019004616A
(es)
|
2016-10-21 |
2019-11-21 |
Samumed Llc |
Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
|
WO2018085171A1
(en)
|
2016-11-01 |
2018-05-11 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors
|
MA46696A
(fr)
|
2016-11-07 |
2019-09-11 |
Samumed Llc |
Formulations injectables à dose unique prêtes à l'emploi
|
IT201700047189A1
(it)
*
|
2017-05-02 |
2018-11-02 |
Fondazione St Italiano Tecnologia |
Composti e composizioni per il trattamento di cancro, disordini della retina e cardiomiopatie
|
AR112027A1
(es)
*
|
2017-06-15 |
2019-09-11 |
Biocryst Pharm Inc |
Inhibidores de alk 2 quinasa que contienen imidazol
|
JP7039802B2
(ja)
|
2017-06-30 |
2022-03-23 |
ベイジン タイド ファーマシューティカル カンパニー リミテッド |
Rho-関連プロテインキナーゼ阻害剤、rho-関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用
|
US10329282B2
(en)
|
2017-06-30 |
2019-06-25 |
Beijing Tide Pharmaceutical Co., Ltd. |
Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
|
JP7311228B2
(ja)
|
2017-06-30 |
2023-07-19 |
ベイジン タイド ファーマシューティカル カンパニー リミテッド |
Rho-関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
|
CN109384774B
(zh)
*
|
2017-08-11 |
2023-02-17 |
中国科学院上海药物研究所 |
一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用
|
BR112020008015A2
(pt)
|
2017-10-27 |
2020-10-27 |
Theravance Biopharma R&D Ip, Llc |
composto derivado da pirimidina como inibidor da quinase jak
|
GB201801226D0
(en)
*
|
2018-01-25 |
2018-03-14 |
Redx Pharma Plc |
Modulators of Rho-associated protein kinase
|
WO2020005935A1
(en)
*
|
2018-06-25 |
2020-01-02 |
Kadmon Corporation, Llc |
Glucose uptake inhibitors
|
CN113164479A
(zh)
|
2018-08-17 |
2021-07-23 |
Ptc医疗公司 |
用于治疗胰腺癌的方法
|
KR102328682B1
(ko)
*
|
2018-08-27 |
2021-11-18 |
주식회사 대웅제약 |
신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
|
WO2020045941A1
(ko)
*
|
2018-08-27 |
2020-03-05 |
주식회사 대웅제약 |
신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
HUE061834T2
(hu)
|
2018-12-27 |
2023-08-28 |
Servier Lab |
MAT2A aza-heterobiciklusos inhibitorai és alkalmazási eljárások rák kezelésére
|
WO2020142748A1
(en)
|
2019-01-03 |
2020-07-09 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Methods and materials for increasing transcription factor eb polypeptide levels
|
US20220133740A1
(en)
|
2019-02-08 |
2022-05-05 |
Frequency Therapeutics, Inc. |
Valproic acid compounds and wnt agonists for treating ear disorders
|
US11384083B2
(en)
|
2019-02-15 |
2022-07-12 |
Incyte Corporation |
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
|
TW202100520A
(zh)
|
2019-03-05 |
2021-01-01 |
美商英塞特公司 |
作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
|
EP3941463A1
(en)
|
2019-03-22 |
2022-01-26 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
KR20210145773A
(ko)
|
2019-03-28 |
2021-12-02 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
티에노헤테로고리형 유도체, 이의 제조 방법 및 이의 의약적 용도
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
KR20210146956A
(ko)
|
2019-03-29 |
2021-12-06 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
피롤로헤테로고리형 유도체, 이의 제조 방법, 및 의약에서 이의 응용
|
CN109826608A
(zh)
*
|
2019-04-08 |
2019-05-31 |
中国科学院地质与地球物理研究所 |
一种分段压裂装置
|
JP7482152B2
(ja)
|
2019-04-24 |
2024-05-13 |
セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー |
皮膚疾患の処置のためのピリミジンjak阻害剤 発明の背景
|
AR118768A1
(es)
|
2019-04-24 |
2021-10-27 |
Theravance Biopharma R&D Ip Llc |
Derivados de pirimidina como inhibidores de las cinasas jak
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
WO2020223469A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
|
JP2022534224A
(ja)
|
2019-05-24 |
2022-07-28 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
置換縮合二環式誘導体、その調製方法、および医薬におけるその適用
|
MA56047A
(fr)
*
|
2019-05-29 |
2022-04-06 |
Ifm Due Inc |
Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting
|
AR119765A1
(es)
|
2019-08-14 |
2022-01-12 |
Incyte Corp |
Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
|
WO2021043966A1
(en)
*
|
2019-09-06 |
2021-03-11 |
Inflazome Limited |
Nlrp3 inhibitors
|
WO2021064142A1
(en)
*
|
2019-10-02 |
2021-04-08 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
|
MX2022004390A
(es)
|
2019-10-11 |
2022-08-08 |
Incyte Corp |
Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2).
|
WO2021173082A1
(en)
*
|
2020-02-26 |
2021-09-02 |
Jaguahr Therapeutics Pte Ltd |
Pyridopyrimidine derivatives useful in modulation of ahr signalling
|
MX2023000521A
(es)
|
2020-07-15 |
2023-02-13 |
Chiesi Farm Spa |
Derivados de piridazinil-amino como inhibidores de el receptor tipo i de factor de crecimiento transformante beta (alk5).
|
WO2022032484A1
(zh)
*
|
2020-08-11 |
2022-02-17 |
北京诺诚健华医药科技有限公司 |
哒嗪-3-甲酰胺类化合物、其制备方法及其在医药学上的应用
|
US20230331731A1
(en)
|
2020-09-29 |
2023-10-19 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Crystal form of pyrrolo heterocyclic derivative and preparation method therefor
|
WO2022107919A1
(ko)
*
|
2020-11-19 |
2022-05-27 |
주식회사 보로노이 |
N을 포함하는 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
CA3223223A1
(en)
|
2021-06-28 |
2023-01-05 |
Blueprint Medicines Corporation |
Cdk2 inhibitors
|
AR127108A1
(es)
|
2021-09-21 |
2023-12-20 |
Chiesi Farm Spa |
Derivados de amino piridazinilo como inhibidores de alk5
|
CN116023380B
(zh)
*
|
2021-10-26 |
2024-01-23 |
沈阳药科大学 |
一类吡唑并嘧啶衍生物及制备方法和应用
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
WO2023135107A1
(en)
|
2022-01-11 |
2023-07-20 |
Chiesi Farmaceutici S.P.A. |
Pyridazinyl amino derivatives as alk5 inhibitors
|